Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rokuro Hama

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Annals of Nutrition & Metabolism|May 1, 2015
Towards a Paradigm Shift in Cholesterol Treatment. A Re-examination of the Cholesterol Issue in JapanTomohito Hamazaki, Harumi Okuyama, Yoichi Ogushi, et al.
Drug, Healthcare and Patient Safety|April 22, 2015
Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional surveyNaoko Takahashi-Ando, Mark A Jones, Shigeki Fujisawa, et al.
The International Journal of Risk & Safety in Medicine|December 14, 2011
Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenzaRokuro Hama, Mark Jones, Hiroki Okushima, et al.
Pharmacology|January 22, 2018
A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017Harumi Okuyama, Tomohito Hamazaki, Rokuro Hama, et al.
Expert Review of Clinical Pharmacology|February 7, 2015
Statins stimulate atherosclerosis and heart failure: pharmacological mechanismsHarumi Okuyama, Peter H Langsjoen, Tomohito Hamazaki, et al.
Lancet (London, England)|October 7, 2014
Neuraminidase inhibitors for influenza complicationsChris Del Mar, Peter Doshi, Rokuro Hama, et al.
The Cochrane Database of Systematic Reviews|January 20, 2012
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and childrenTom Jefferson, Mark A Jones, Peter Doshi, et al.
BMJ Open|October 2, 2014
Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reportsTom Jefferson, Mark A Jones, Peter Doshi, et al.
Expert Review of Clinical Pharmacology|January 8, 2021
The new European guidelines for prevention of cardiovascular disease are misleadingUffe Ravnskov, Abdullah Alabdulgader, Michel de Lorgeril, et al.
Health Technology Assessment (Winchester, England)|June 2, 2016
Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality dataCarl J Heneghan, Igho Onakpoya, Mark A Jones, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Annals of Nutrition & Metabolism|May 1, 2015
Towards a Paradigm Shift in Cholesterol Treatment. A Re-examination of the Cholesterol Issue in JapanTomohito Hamazaki, Harumi Okuyama, Yoichi Ogushi, et al.
Drug, Healthcare and Patient Safety|April 22, 2015
Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional surveyNaoko Takahashi-Ando, Mark A Jones, Shigeki Fujisawa, et al.
The International Journal of Risk & Safety in Medicine|December 14, 2011
Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenzaRokuro Hama, Mark Jones, Hiroki Okushima, et al.
Pharmacology|January 22, 2018
A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017Harumi Okuyama, Tomohito Hamazaki, Rokuro Hama, et al.
Expert Review of Clinical Pharmacology|February 7, 2015
Statins stimulate atherosclerosis and heart failure: pharmacological mechanismsHarumi Okuyama, Peter H Langsjoen, Tomohito Hamazaki, et al.
Lancet (London, England)|October 7, 2014
Neuraminidase inhibitors for influenza complicationsChris Del Mar, Peter Doshi, Rokuro Hama, et al.
The Cochrane Database of Systematic Reviews|January 20, 2012
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and childrenTom Jefferson, Mark A Jones, Peter Doshi, et al.
BMJ Open|October 2, 2014
Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reportsTom Jefferson, Mark A Jones, Peter Doshi, et al.
Expert Review of Clinical Pharmacology|January 8, 2021
The new European guidelines for prevention of cardiovascular disease are misleadingUffe Ravnskov, Abdullah Alabdulgader, Michel de Lorgeril, et al.
Health Technology Assessment (Winchester, England)|June 2, 2016
Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality dataCarl J Heneghan, Igho Onakpoya, Mark A Jones, et al.
Pageof 3